Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tim A. Plunkett"'
Autor:
Robert Sewell, Joy Burchell, Tim A. Plunkett, Rosalind Graham, Isobel Correa, Joyce Taylor-Papadimitriou, David Miles
Publikováno v:
International Journal of Cancer. 109:691-697
Using a C57Bl/6 mouse model system, where intramuscular (i.m.) injection of full length (FL) MUC1 cDNA protects against subsequent challenge with MUC1-expressing syngeneic tumour cells, we have investigated the importance of the tandem repeat (TR) do
Publikováno v:
Clinical Lung Cancer. 5:28-32
Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patient
Publikováno v:
Expert Review of Anticancer Therapy. 1:441-445
Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropr
Autor:
Deborah J. Hopster, Peter Harper, Stephanie E. Munn, James S.M. Yeh, Tim A. Plunkett, Anthony W. du Vivier
Publikováno v:
Journal of the American Academy of Dermatology. 42:357-362
The association of acanthosis nigricans (AN) with the sign of Leser-Trélat (LT) and gastric carcinoma is rare. Our patient was a 69-year-old man, who presented with hematemesis; a stage-IV poorly differentiated, diffuse-type, adenocarcinoma of the g
Autor:
Tim A. Plunkett, Olivera J. Finn, Anda M. Vlad, Arron Mungul, Joyce Taylor-Papadimitriou, Jessica Candelora-Kettel, Isabel Correa, Joy Burchell
MUC1 is a transmembrane mucin that is expressed on ductal epithelial cells and epithelial malignancies and has been proposed as a target antigen for immunotherapy. The expression of MUC1 has recently been reported on T and B cells. In this study we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804130d7c67c879aae2de20e5d2342cd
https://europepmc.org/articles/PMC1782871/
https://europepmc.org/articles/PMC1782871/
Autor:
Isabel Correa, Tim A. Plunkett
Publikováno v:
Breast Cancer Research
During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10-40% of breast cancers and other carcinoma